Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Viking Systems' first-quarter 2010 sales up 26%

Viking Systems, Inc. today announced financial results for its first quarter ended March 31, 2010. The Company reported a 26% increase in sales to $1,915,073 for the quarter ended March 31, 2010 and a net loss of $295,450 or ($0.01) per share.

5 May 2010

AMRI first-quarter total revenue down 9% to $49.3 million

AMRI today reported financial and operating results for the first quarter ended March 31, 2010.

5 May 2010

Merck acquires development, commercialization rights of ridaforolimus

Merck today announced that it has restructured its co-development and co-commercialization agreement with ARIAD Pharmaceuticals, Inc. for ridaforolimus, an investigational orally available mTOR inhibitor currently being evaluated for the treatment of multiple cancer types, to an exclusive license agreement.

5 May 2010

ARIAD restructures collaboration with Merck for ridaforolimus mTOR inhibitor

ARIAD Pharmaceuticals, Inc. today announced that it has restructured its July 2007 collaboration with Merck, Sharpe & Dohme Corp. for the development, manufacture, and commercialization of ridaforolimus - ARIAD's investigational mTOR inhibitor.

5 May 2010

Abbott announces opening of Asia-Pacific Nutrition R&D Center

Abbott, the global health care company, today announced the opening of the Abbott Asia-Pacific Nutrition Research & Development Center at Singapore's Biopolis Research Park. The center is Abbott's largest nutrition R&D facility outside of the U.S., and Singapore's first nutrition R&D site creating science-based nutritional products for infants, children and adults.

5 May 2010

New treatments for intestinal failure, other intestinal absorption disorders

New treatments for intestinal failure and other intestinal absorption disorders are a step closer to the patients who need them after a discovery in Kelly Tappenden's University of Illinois laboratory.

5 May 2010

Particle Sciences extends collaboration with Microfluidics to implement MRT system

Particle Sciences and Microfluidics extended their collaboration with the placement of the newly-announced Microfluidics Reaction Technology system at Particle Sciences.

5 May 2010

ZEGERID OTC capsules offer more rapid acid reduction than Prevacid- 24HR delayed-release capsules

Merck Consumer Care today announced results of a head-to-head clinical study showing that ZEGERID OTC- offers greater and faster acid control than Prevacid- 24HR. While acid control is an industry standard measure for acid-reducing drugs, greater and faster acid control does not imply greater and faster heartburn symptom relief.

5 May 2010

Pfizer's first-quarter 2010 revenues increase 54% to $16.8 billion

Pfizer Inc. today reported financial results for first-quarter 2010. Since the acquisition of Wyeth was completed on October 15, 2009, legacy Wyeth operations are reflected in first-quarter 2010 results, but not in first-quarter 2009 results. First-quarter 2010 revenues were $16.8 billion, an increase of 54% compared with $10.9 billion in the year-ago quarter.

5 May 2010

Cambrex first-quarter sales down 6.4% to $56.2 million

Cambrex Corporation reports first quarter results for the period ended March 31, 2010.

4 May 2010

Theragenics reports highest quarterly consolidated revenue of $20.3 million

Theragenics Corporation®, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2010.

4 May 2010

FDA grants market clearance for Illumina's BeadXpress system for multiplex genetic analysis

Illumina, Inc. today announced that the U.S. Food and Drug Administration has granted 510(k) market clearance for the company's BeadXpress system for multiplex genetic analysis.

From Illumina, Inc. 4 May 2010

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the Cell Culture Engineering XII conference held in Alberta, Canada from April 25 - 30, 2010. Alnylam Biotherapeutics was formed by Alnylam to develop RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies.

4 May 2010

FDA orders Baxter Healthcare to recall and destroy all Colleague infusion pumps

The U.S. Food and Drug Administration sent a letter to Baxter Healthcare Corp. on April 30 ordering the company to recall and destroy all of its Colleague Volumetric Infusion Pumps (Colleague pumps) currently in use in the United States. This action is based on a longstanding failure to correct many serious problems with the pumps. The FDA believes there may be as many as 200,000 of those pumps currently in use.

4 May 2010

ADVENTRX Pharmaceuticals announces 6-month stability data for Exelbine

ADVENTRX Pharmaceuticals, Inc. today announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion), or Exelbine™, manufactured at the Company's intended commercial manufacturing site. The 6-month stability data are on track to support the submission of the New Drug Application (NDA) for Exelbine.

4 May 2010

Hormone-like inner ear signaling system protects against noise-induced hearing loss

An in vivo study shows for the first time that there is a stress-response system within the cochlea that mirrors the signaling pathways of the body's fight or flight response. Researchers have identified a hormone-like signaling system of the inner ear that sets baseline hearing sensitivity and helps protect against noise-induced hearing loss.

4 May 2010

Boost for biologics manufacturing in Australia

AusBiotech has welcomed the news that Australia’s first major contract manufacturing facility for biologic medicines has secured backing and is set to be built in Queensland by 2012.

3 May 2010

BioTime acquires ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of human stem cells and regenerative medicine, today announced that it has completed its acquisition of the Singapore company ES Cell International Pte Ltd.

3 May 2010

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

3 May 2010

Vascular Solutions acquires Escalon Medical's SMARTNEEDLE, pdACCESS businesses

Vascular Solutions, Inc. today announced that it has acquired the assets related to the SMARTNEEDLE™ and pdACCESS™ Doppler guided needle access business from Escalon Vascular Access, Inc., a division of Escalon Medical Corporation. The SMARTNEEDLE and pdACCESS products consist of a hand-held monitor and one-time use needles designed to provide auditory ultrasound guided access to arteries and veins during catheterization procedures.

3 May 2010